How big is the Vietnam Oral Anti-Diabetic Drug Market?

January 2024: Lupin gets USFDA approval to market generic medication to treat diabetes.
November 2022: A pre-post study was Conducted which aimed to evaluate the impact of a peer-based club intervention to improve self-management among people living with T2D in two rural communities in Vietnam.

The Vietnam Oral Anti-Diabetic Drug Market size is expected to reach USD 156.21 million in 2024 and grow at a CAGR of greater than 4% to reach USD 195.32 million by 2029. Read More

What is the current Vietnam Oral Anti-Diabetic Drug Market size?

In 2024, the Vietnam Oral Anti-Diabetic Drug Market size is expected to reach USD 156.21 million. Read More

Who are the key players in Vietnam Oral Anti-Diabetic Drug Market?

Astrazeneca, Astellas, Janssen, Eli Lilly and Sanofi are the major companies operating in the Vietnam Oral Anti-Diabetic Drug Market. Read More

What years does this Vietnam Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?

In 2023, the Vietnam Oral Anti-Diabetic Drug Market size was estimated at USD 149.96 million. The report covers the Vietnam Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Vietnam Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Vietnam Oral Anti-Diabetic Drug Companies

This report lists the top Vietnam Oral Anti-Diabetic Drug companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Vietnam Oral Anti-Diabetic Drug industry.